This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Michael Jarvis

Dr Michael Jarvis


Dr Michael Jarvis FBPhS


Abbvie, Inc.

Year elected:


Primary professional setting:


Mike has extensive experience in all phases of drug discovery research from target identification and validation through drug candidate selection and clinical development including Phase-II proof of concept studies and drug life-cycle management. He has effectively led multidisciplinary research teams to generate state-of-the-art scientific advances in pharmacology, molecular biology, neurophysiology and medicinal chemistry targeting multiple therapeutic areas. He has published more than 240 peer-reviewed papers (H-index = 65). In his current Medical Affairs role, he provides scientific and medical oversight of established therapies for epilepsy, pain and dyslipidemia as well as supporting late-stage development of novel therapies for cystic fibrosis. He is a former Editor-in-Chief of ASPET’s Journal of Pharmacology and Experimental Therapeutics and a past reviewing editor for the British Journal of Pharmacology. He is the current Deputy Editor of the ASPET/BPS/Wiley collaborative open access journal, Pharmacology Research & Perspectives.